Cambridge Investment Research Advisors’s Pacer BioThreat Strategy ETF VIRS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VIRS Stock Details VIRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,655	Closed	-$206K	–	3242
2022 Q1	$206K	Sell	6,655 -1,124	-14%	-$35K	﹤0.01%	2847
2021 Q4	$271K	Hold	7,779	–	–	﹤0.01%	2625
2021 Q3	$253K	Buy	7,779 +1	+0%	+$33	﹤0.01%	2614
2021 Q2	$247K	Sell	7,778 -1,599	-17%	-$48.6K	﹤0.01%	2622
2021 Q1	$272K	Sell	9,377 -1,708	-15%	-$49.4K	﹤0.01%	2352
2020 Q4	$310K	Buy	11,085 +346	+3%	+$9.73K	﹤0.01%	2108
2020 Q3	$299K	Buy	+10,739	New	+$289K	﹤0.01%	1932

Other funds holding VIRS

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cambridge Investment Research Advisors's VIRS Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Pacer BioThreat Strategy ETF (VIRS) in Q2 2022, closing a stake of 6,655 shares — an estimated $206K sold.

Cambridge Investment Research Advisors first reported a position in VIRS in Q3 2020 and held it in 7 quarters. The position peaked at $310K in Q4 2020. 4 funds tracked by Wall St. Rank hold VIRS as of Q2 2022.

Cambridge Investment Research Advisors reported no remaining Pacer BioThreat Strategy ETF position as of Q2 2022 after selling out during the quarter.
Cambridge Investment Research Advisors sold 6,655 Pacer BioThreat Strategy ETF shares in Q2 2022, an estimated $206K.
Cambridge Investment Research Advisors first reported a position in Pacer BioThreat Strategy ETF in Q3 2020 and held it in 7 quarters.
Cambridge Investment Research Advisors's Pacer BioThreat Strategy ETF position peaked at $310K in Q4 2020.
4 funds tracked by Wall St. Rank held Pacer BioThreat Strategy ETF as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.